Edition:
United States

Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

81.59USD
22 Jul 2016
Change (% chg)

$1.19 (+1.48%)
Prev Close
$80.40
Open
$80.40
Day's High
$81.71
Day's Low
$80.30
Volume
1,271,386
Avg. Vol
1,302,395
52-wk High
$92.83
52-wk Low
$67.88

LLY.N

Chart for LLY.N

About

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.... (more)

Overall

Beta: 0.21
Market Cap(Mil.): $90,115.53
Shares Outstanding(Mil.): 1,104.49
Dividend: 0.51
Yield (%): 2.50

Financials

  LLY.N Industry Sector
P/E (TTM): 37.45 36.15 37.05
EPS (TTM): 2.18 -- --
ROI: 8.49 15.11 14.35
ROE: 15.50 16.17 15.56

Fitch Affirms Eli Lilly's IDR at 'A'; Outlook Stable

(The following statement was released by the rating agency) CHICAGO, July 22 (Fitch) Fitch Ratings has affirmed Eli Lilly & Co. Inc.'s (Lilly) Long-Term Issuer Default Rating (IDR) at 'A' with a Stable Outlook. Fitch also affirmed the company's short-term IDR at 'F1'. The rating actions apply to roughly $7.8 billion of debt outstanding at Mar. 31, 2016. A full list of the rating actions is provided at the end of this release. KEY RATING DRIVERS --Lilly is facing a manageable patent expiry pe

Jul 22 2016

BRIEF-Eli Lilly, U.S. FDA expand indication for type 2 diabetes treatment Synjardy

* U.S. FDA expands indication for type 2 diabetes treatment Synjardy (empagliflozin/metformin hydrochloride) to include treatment-naïve adults

Jul 19 2016

BRIEF-Eli Lilly sets quarterly dividend of $0.51/shr

* Sets quarterly dividend of $0.51 per share Source text for Eikon: Further company coverage:

Jun 20 2016

BRIEF-Lilly names Aarti Shah Chief Information Officer

* Promotion of Aarti Shah , Ph.D., to Senior Vice President and Chief Information Officer effective July 1

Jun 13 2016

Independence of compliance reviews is questioned in drug firm settlements

WASHINGTON Some major U.S. drug companies have hired their own auditors to perform compliance reviews mandated in government settlements over alleged civil violations, such as paying kickbacks or off-label drug promotion, according to federal records reviewed by Reuters.

Jun 02 2016

Independence of compliance reviews is questioned in drug firm settlements

WASHINGTON, June 2 Some major U.S. drug companies have hired their own auditors to perform compliance reviews mandated in government settlements over alleged civil violations, such as paying kickbacks or off-label drug promotion, according to federal records reviewed by Reuters.

Jun 02 2016

BRIEF-FDA grants priority review for Lilly's Olaratumab

* FDA grants priority review for lilly's Olaratumab, an investigational medicine for advanced soft tissue sarcoma

May 04 2016

BRIEF-Eli Lilly sets quarterly dividend of $0.51/shr

* Sets quarterly dividend of $0.51 per share Source text for Eikon: Further company coverage:

May 02 2016

Pharmacy stuck in Cialis patent war between Eli Lilly, German firm

A federal judge in Texas has blocked a Texas pharmacy chain's early exit from the patent war between Eli Lilly and a German pharmaceutical firm over the use of the erectile dysfunction drug Cialis to treat the prostate condition known as BPH.

Apr 28 2016

Boehringer's operating profit up 6 percent on diabetes drugs

FRANKFURT, April 19 Boehringer Ingelheim, Germany's second-largest drugmaker, posted 11 percent higher sales and a 6 percent gain in operating profit for 2015, boosted by its diabetes treatment business, where it collaborates with Eli Lilly.

Apr 19 2016

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $125.03 -0.12
Pfizer Inc. (PFE.N) $36.74 +0.03
Novartis AG (NOVN.S) CHF82.35 +0.40
Merck & Co., Inc. (MRK.N) $58.82 +0.03
Abbott Laboratories (ABT.N) $43.17 +0.13
Sanofi SA (SASY.PA) €76.60 +0.38
AstraZeneca plc (AZN.L) 4,612.50p +89.00
GlaxoSmithKline plc (GSK.L) 1,659.50p +21.50
Bristol-Myers Squibb Co (BMY.N) $75.68 +0.18
Bristol-Myers Squibb Co (BMYMP.PK) $1,231.90 --

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : Stock Traders Daily
$20.00
Provider : Reuters Investment Profile
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.